Zoetis Inc. (ZTS) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

10/25

Growth 1 Margin 2 Expansion 4 Platform 0 Financial 3

latest quarter score

Earnings Reports

10
Zoetis (ZTS) Q2 2026: Gross-to-Net Rebates Drive 2% Price Compression as Competitive Pressures Intensify
August 06, 2026
22
Zoetis (ZTS) Q4 2025: Semperica Trio Hits $1B U.S. Milestone Amid 12% Franchise Growth
June 15, 2026
15
Zoetis (ZTS) Q1 2026: U.S. Companion Animal Revenue Down 11% as Competitive Pressure and Price Sensitivity Bite
May 07, 2026
21
Zoetis (ZTS) Q3 2025: Livestock Grows 10% as Companion Animal Volume Stalls
November 04, 2025
23
Zoetis (ZTS) Q2 2025: Semperica Trio Grows 20%, Reinforcing First-Mover Edge in Expanding Parasiticide Market
August 05, 2025
20
Zoetis (ZTS) Q1 2025: Companion Animal Franchises Drive 14% Growth as Retail Channel Hits 21% of U.S. Sales
June 30, 2025

Browse all companies